140 related articles for article (PubMed ID: 35081092)
1. Comparison of reprojected bone SPECT/CT and planar bone scintigraphy for the detection of bone metastases in breast and prostate cancer.
Arvola S; Seppänen M; Malaspina S; Mätzke S; Raiko J; Timonen KL; Ettala O; Jambor I; Anttinen M; Kuisma A; Löyttyniemi E; Boström PJ; Sohlberg A; Noponen T
Nucl Med Commun; 2022 May; 43(5):510-517. PubMed ID: 35081092
[TBL] [Abstract][Full Text] [Related]
2. Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial.
Jambor I; Kuisma A; Ramadan S; Huovinen R; Sandell M; Kajander S; Kemppainen J; Kauppila E; Auren J; Merisaari H; Saunavaara J; Noponen T; Minn H; Aronen HJ; Seppänen M
Acta Oncol; 2016; 55(1):59-67. PubMed ID: 25833330
[TBL] [Abstract][Full Text] [Related]
3. A Prospective Comparison of
Anttinen M; Ettala O; Malaspina S; Jambor I; Sandell M; Kajander S; Rinta-Kiikka I; Schildt J; Saukko E; Rautio P; Timonen KL; Matikainen T; Noponen T; Saunavaara J; Löyttyniemi E; Taimen P; Kemppainen J; Dean PB; Blanco Sequeiros R; Aronen HJ; Seppänen M; Boström PJ
Eur Urol Oncol; 2021 Aug; 4(4):635-644. PubMed ID: 32675047
[TBL] [Abstract][Full Text] [Related]
4. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT.
Even-Sapir E; Metser U; Mishani E; Lievshitz G; Lerman H; Leibovitch I
J Nucl Med; 2006 Feb; 47(2):287-97. PubMed ID: 16455635
[TBL] [Abstract][Full Text] [Related]
5. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
6. Inter-observer variability between readers in detection of bone metastases comparing different modalities; PET/CT, SPECT/CT and planar bone scintigraphy.
Bashank N; Hussein A; Mekawy M; Askar H
Nucl Med Commun; 2023 Jul; 44(7):604-612. PubMed ID: 37114413
[TBL] [Abstract][Full Text] [Related]
7. Comparison of bone scintigraphy and
Pyka T; Okamoto S; Dahlbender M; Tauber R; Retz M; Heck M; Tamaki N; Schwaiger M; Maurer T; Eiber M
Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2114-2121. PubMed ID: 27290607
[TBL] [Abstract][Full Text] [Related]
8. Bone scintigraphy as a gatekeeper for the detection of bone metastases in patients with prostate cancer: comparison with Ga-68 PSMA PET/CT.
Caglar M; Tuncel M; Yildiz E; Karabulut E
Ann Nucl Med; 2020 Dec; 34(12):932-941. PubMed ID: 32975741
[TBL] [Abstract][Full Text] [Related]
9. Optimizing PSMA scintigraphy for resource limited settings - a retrospective comparative study.
Kolade OU; Brink A; Ayeni AO; More S; Holness J
Cancer Imaging; 2024 Apr; 24(1):46. PubMed ID: 38556864
[TBL] [Abstract][Full Text] [Related]
10. Prospective comparative study of
Fonager RF; Zacho HD; Langkilde NC; Fledelius J; Ejlersen JA; Hendel HW; Haarmark C; Moe M; Mortensen JC; Jochumsen MR; Petersen LJ
Acta Oncol; 2018 Aug; 57(8):1063-1069. PubMed ID: 29447047
[TBL] [Abstract][Full Text] [Related]
11. Comparison of PSMA-PET/CT, choline-PET/CT, NaF-PET/CT, MRI, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a systematic review and meta-analysis.
Zhou J; Gou Z; Wu R; Yuan Y; Yu G; Zhao Y
Skeletal Radiol; 2019 Dec; 48(12):1915-1924. PubMed ID: 31127357
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer.
Qiu ZL; Xue YL; Song HJ; Luo QY
Nucl Med Commun; 2012 Dec; 33(12):1232-42. PubMed ID: 23111353
[TBL] [Abstract][Full Text] [Related]
13. Detection of the Prostate Cancer Bone Metastases: Is It Feasible to Compare 18F-fluorocholine PET/CT, 18F-fluorodeoxyglucose PET/CT and 99mTc-methyl Diphosphonate Bone Scintigraphy?
Pietrzak AK; Czepczynski R; Wierzchoslawska E; Cholewinski W
Urol J; 2018 Sep; 15(5):242-247. PubMed ID: 29681049
[TBL] [Abstract][Full Text] [Related]
14. Prospective comparison of whole-body bone SPECT and sodium 18F-fluoride PET in the detection of bone metastases from breast cancer.
Abikhzer G; Srour S; Fried G; Drumea K; Kozlener E; Frenkel A; Israel O; Fogelman I; Kagna O
Nucl Med Commun; 2016 Nov; 37(11):1160-8. PubMed ID: 27536906
[TBL] [Abstract][Full Text] [Related]
15.
Wondergem M; van der Zant FM; Knol RJJ; Burgers AMG; Bos SD; de Jong IJ; Pruim J
World J Urol; 2018 Jan; 36(1):27-34. PubMed ID: 29043431
[TBL] [Abstract][Full Text] [Related]
16.
Lengana T; Lawal IO; Boshomane TG; Popoola GO; Mokoala KMG; Moshokoa E; Maes A; Mokgoro NP; Van de Wiele C; Vorster M; Sathekge MM
Clin Genitourin Cancer; 2018 Oct; 16(5):392-401. PubMed ID: 30120038
[TBL] [Abstract][Full Text] [Related]
17. Inter- and intraobserver agreement in standard and ultra-fast single-photon emission computed tomography/computed tomography for the assessment of bone metastases.
Zacho HD; Aleksyniene R; Ejlersen JA; Fledelius J; Petersen LJ
Nucl Med Commun; 2020 Oct; 41(10):1005-1009. PubMed ID: 32694282
[TBL] [Abstract][Full Text] [Related]
18. Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer?
Lecouvet FE; El Mouedden J; Collette L; Coche E; Danse E; Jamar F; Machiels JP; Vande Berg B; Omoumi P; Tombal B
Eur Urol; 2012 Jul; 62(1):68-75. PubMed ID: 22366187
[TBL] [Abstract][Full Text] [Related]
19. Single photon emission computed tomography (SPECT) and SPECT/low-dose computerized tomography did not increase sensitivity or specificity compared to planar bone scintigraphy for detection of bone metastases in advanced breast cancer.
Haraldsen A; Bluhme H; Røhl L; Pedersen EM; Jensen AB; Hansen EB; Nellemann H; Rasmussen F; Morsing A
Clin Physiol Funct Imaging; 2016 Jan; 36(1):40-6. PubMed ID: 25257661
[TBL] [Abstract][Full Text] [Related]
20. Transitioning to whole-body SPECT/CT in prostate cancer staging: a new concept for a better imaging workflow.
Weissinger M; Kupferschläger J; La Fougère C; Dittmann H; Fiz F
Nuklearmedizin; 2019 Dec; 58(6):451-459. PubMed ID: 31711243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
